clinical trial · NCT07152223
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Guangzhou Bio-gene Technology Co., Ltd·N/A·recruiting·n = 20
Connective Tissue DiseasesCAR-T
brief summary
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
started
Aug 30, 2025
primary completion
Aug 31, 2029
completion
Aug 31, 2029
last updated
Sep 3, 2025
official title
A Single-center Clinical Study to Evaluate the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol